Literature DB >> 15133818

Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations.

Meltem Müftüoglu1, Bülent Elibol, Ozlem Dalmizrak, Ayse Ercan, Gülnihal Kulaksiz, Hamdi Ogüs, Turgay Dalkara, Nazmi Ozer.   

Abstract

The parkin protein functions as a RING-type ubiquitin protein ligase. Considering the possibility that impaired ubiquitin-proteosomal system activity may impair antioxidant defenses and enhance oxidative stress, we have investigated the activity of mitochondrial respiratory enzymes in patients with parkin gene mutations. A significant decrease in the leukocyte complex I activity was found both in patients with parkin mutations (62.5%) and idiopathic PD (64.5%) compared with age-matched controls (P < 0.001). Complex IV activity was also decreased significantly in idiopathic PD patients (60%), but no difference was detected between controls and patients with parkin mutations. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133818     DOI: 10.1002/mds.10695

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  78 in total

1.  Regulation of complex I by Engrailed is complex too.

Authors:  Laurie H Sanders; J Timothy Greenamyre
Journal:  Nat Neurosci       Date:  2011-09-27       Impact factor: 24.884

Review 2.  Potential future neuroprotective therapies for neurodegenerative disorders and stroke.

Authors:  Rawan Tarawneh; James E Galvin
Journal:  Clin Geriatr Med       Date:  2010-02       Impact factor: 3.076

Review 3.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 4.  The role of parkin in familial and sporadic Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

Review 5.  Parkin and PINK1 functions in oxidative stress and neurodegeneration.

Authors:  Sandeep K Barodia; Rose B Creed; Matthew S Goldberg
Journal:  Brain Res Bull       Date:  2016-12-23       Impact factor: 4.077

Review 6.  Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes.

Authors:  Laura Scott; Valina L Dawson; Ted M Dawson
Journal:  Exp Neurol       Date:  2017-04-23       Impact factor: 5.330

7.  PARK2 variability in Polish Parkinson's disease patients--interaction with mitochondrial haplogroups.

Authors:  Katarzyna Gaweda-Walerych; Krzysztof Safranow; Barbara Jasinska-Myga; Monika Bialecka; Gabriela Klodowska-Duda; Monika Rudzinska; Krzysztof Czyzewski; Stephanie A Cobb; Jaroslaw Slawek; Maria Styczynska; Grzegorz Opala; Marek Drozdzik; Kenya Nishioka; Matthew J Farrer; Owen A Ross; Zbigniew K Wszolek; Maria Barcikowska; Cezary Zekanowski
Journal:  Parkinsonism Relat Disord       Date:  2012-02-22       Impact factor: 4.891

Review 8.  Parkinson's disease: an update on pathogenesis and treatment.

Authors:  Tom Foltynie; Joshua Kahan
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

9.  PINK1 is selectively stabilized on impaired mitochondria to activate Parkin.

Authors:  Derek P Narendra; Seok Min Jin; Atsushi Tanaka; Der-Fen Suen; Clement A Gautier; Jie Shen; Mark R Cookson; Richard J Youle
Journal:  PLoS Biol       Date:  2010-01-26       Impact factor: 8.029

10.  Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.

Authors:  Luke S Tain; Heather Mortiboys; Ran N Tao; Elena Ziviani; Oliver Bandmann; Alexander J Whitworth
Journal:  Nat Neurosci       Date:  2009-08-16       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.